Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2022 financial results and provided a corporate update.

View Full Press Release

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics Announces Proposed Public Offering of Common Stock